Literature DB >> 16893422

Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system.

Steve Poirier1, Annik Prat, Edwige Marcinkiewicz, Joanne Paquin, Babykumari P Chitramuthu, David Baranowski, Benoit Cadieux, Hugh P J Bennett, Nabil G Seidah.   

Abstract

Neural apoptosis-regulated convertase-1/proprotein convertase subtilisin-kexin like-9 (NARC-1/PCSK9) is a proprotein convertase recently described to play a major role in cholesterol homeostasis through enhanced degradation of the low-density lipoprotein receptor (LDLR) and possibly in neural development. Herein, we investigated the potential involvement of this proteinase in the development of the CNS using mouse embryonal pluripotent P19 cells and the zebrafish as models. Time course quantitative RT-PCR analyses were performed following retinoic acid (RA)-induced neuroectodermal differentiation of P19 cells. Accordingly, the mRNA levels of NARC-1/PCSK9 peaked at day 2 of differentiation and fell off thereafter. In contrast, the expression of the proprotein convertases subtilisin kexin isozyme 1/site 1 protease and Furin was unaffected by RA, whereas that of PC5/6 and PC2 increased within and/or after the first 4 days of the differentiation period respectively. This pattern was not affected by the cholesterogenic transcription factor sterol regulatory element-binding protein-2, which normally up-regulates NARC-1/PCSK9 mRNA levels in liver. Furthermore, in P19 cells, RA treatment did not affect the protein level of the endogenous LDLR. This agrees with the unique expression pattern of NARC-1/PCSK9 in the rodent CNS, including the cerebellum, where the LDLR is not significantly expressed. Whole-mount in situ hybridization revealed that the pattern of expression of zebrafish NARC-1/PCSK9 is similar to that of mouse both in the CNS and periphery. Specific knockdown of zebrafish NARC-1/PCSK9 mRNA resulted in a general disorganization of cerebellar neurons and loss of hindbrain-midbrain boundaries, leading to embryonic death at approximately 96 h after fertilization. These data support a novel role for NARC-1/PCSK9 in CNS development, distinct from that in cholesterogenic organs such as liver.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16893422     DOI: 10.1111/j.1471-4159.2006.03928.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  32 in total

1.  PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke.

Authors:  Estelle Rousselet; Jadwiga Marcinkiewicz; Jasna Kriz; Ann Zhou; Mary E Hatten; Annik Prat; Nabil G Seidah
Journal:  J Lipid Res       Date:  2011-04-25       Impact factor: 5.922

2.  PCSK9 is Increased in Cerebrospinal Fluid of Individuals With Alcohol Use Disorder.

Authors:  Ji Soo Lee; Daniel Rosoff; Audrey Luo; Martha Longley; Monte Phillips; Katrin Charlet; Christine Muench; Jeesun Jung; Falk W Lohoff
Journal:  Alcohol Clin Exp Res       Date:  2019-05-03       Impact factor: 3.455

3.  Using Human 'Experiments of Nature' to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors.

Authors:  Rebecca N Jerome; Jill M Pulley; Dan M Roden; Jana K Shirey-Rice; Lisa A Bastarache; Gordon R Bernard; Leeland B Ekstrom; William J Lancaster; Joshua C Denny
Journal:  Drug Saf       Date:  2018-03       Impact factor: 5.606

4.  Proprotein convertase subtilisin/kexin type 7 (PCSK7) is essential for the zebrafish development and bioavailability of transforming growth factor β1a (TGFβ1a).

Authors:  Hannu Turpeinen; Anna Oksanen; Virpi Kivinen; Sampo Kukkurainen; Annemari Uusimäki; Mika Rämet; Mataleena Parikka; Vesa P Hytönen; Matti Nykter; Marko Pesu
Journal:  J Biol Chem       Date:  2013-10-31       Impact factor: 5.157

5.  PCSK9 regulates apoptosis in human neuroglioma u251 cells via mitochondrial signaling pathways.

Authors:  Ming-Xue Piao; Ji-Wei Bai; Peng-Fei Zhang; Ya-Zhuo Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

6.  Genetics: a gene of rare effect.

Authors:  Stephen S Hall
Journal:  Nature       Date:  2013-04-11       Impact factor: 49.962

Review 7.  Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.

Authors:  Giuseppe Danilo Norata; Hagai Tavori; Angela Pirillo; Sergio Fazio; Alberico L Catapano
Journal:  Cardiovasc Res       Date:  2016-08-05       Impact factor: 10.787

Review 8.  Molecular biology of PCSK9: its role in LDL metabolism.

Authors:  Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal:  Trends Biochem Sci       Date:  2007-01-09       Impact factor: 13.807

Review 9.  Zebrafish models of dyslipidemia: relevance to atherosclerosis and angiogenesis.

Authors:  Longhou Fang; Chao Liu; Yury I Miller
Journal:  Transl Res       Date:  2013-10-02       Impact factor: 7.012

Review 10.  PCSK9 Inhibitors: potential in cardiovascular therapeutics.

Authors:  Rose Q Do; Robert A Vogel; Gregory G Schwartz
Journal:  Curr Cardiol Rep       Date:  2013-03       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.